RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 4, 2020

Primary Completion Date

November 22, 2022

Study Completion Date

November 22, 2022

Conditions

Solid Tumor, Unspecified, Adult

Interventions

DRUG

RLY-1971

RLY-1971 is an oral inhibitor of SHP2.

Trial Locations (6)

Florida Cancer Specialist-Lake Mary, Lake Mary

Florida Cancer Specialists - Sarasota, Sarasota

Tennessee Oncology; Sarah Cannon Research Institute, Nashville

Massachusetts General Hospital Cancer Center, Boston

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT04252339 - RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter